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ABSTRACT 
Objective: To develop the method for the simultaneous analysis of cyclophosphamide and 4-hydroxycyclophosphamide (4-OHCP) in Dried Blood 
Spot (DBS) using Ultra-High-Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS) and its application in breast cancer 
patients for therapeutic drug monitoring. 
Methods: Sample preparation used protein precipitation with methanol and acetonitrile (2:1 v/v). The separation was conducted using 1.7μm (2.1 
x 100 mm) Waters AcquityTM
Results: The method was linear in the range of 50–30.000 ng/ml for cyclophosphamide and 10–1000 ng/ml for 4-OHCP. Lower Limit of 
Quantification (LLOQ) concentration of cyclophosphamide was 50 ng/ml and 4-OHCP was 10 ng/ml. Accuracy and precision within-run and 
between-run met the requirements with % diff and CV, not exceeding ±15% and not more than ±20% for LLOQ concentration. The results from DBS 
samples of cancer patients showed that the level of cyclophosphamide was in the range of 6045.980 ng/ml to 37024.403 ng/ml and 4-OHCP was in 
the range 33.155 ng/ml to 246.362 ng/ml. 
 UPLC C18 column; mobile phase consists of 0.01% formic acid and methanol (50:50 v/v) with isocratic elution, column 
temperature 30 °C, flow rate 0.3 ml/min and hexamethylphosphoramide (HMP) used as an internal standard. Analysis was performed by a triple 
quadrupole mass spectrometry with a positive ion mode of Electrospray Ionization. Cyclophosphamide was detected at m/z 260.968>139.978, 4-
OHCP at m/z 338.011>224.979, and HMP at m/z 180.17>92.08. The method was applied to quantify cyclophosphamide and 4-OHCP in DBS of 
breast cancer patients. Blood samples were collected at 2 and 4 h after cyclophosphamide administration for therapeutic drug monitoring. 
Conclusion: The developed method met the requirements of all validation parameters under the Guideline on Bioanalytical Method Validation 
by the European Medicines Agency in 2011. Method can be applied on DBS of cancer patients and the results showed that cyclophosphamide 
and 4-OHCP was detected on 17 samples of breast cancer patients. This can be one of the parameters for therapeutic drug monitoring. 
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INTRODUCTION 
Cyclophosphamide is an anticancer drug that acts as an alkylating 
agent and is used singly, as well as being a regimen in multiple types 
of cancer therapies such as non-Hodgkin's lymphoma, sarcoma, and 
breast cancer [1]. Cyclophosphamide is a prodrug that requires 
activation by the cytochrome P450 enzyme to convert into its active 
metabolite, 4-OHCP. This metabolite is in balance with its tautomeric 
form, aldophosphamide, which will become its active form, 
phosphoramide mustard and acrolein [2]. The number of enzymes 
that play a role in the metabolism of cyclophosphamide can cause 
various expressions and activities among patients, thus contributing 
to the metabolism, efficacy and toxicity of this drug [3]. Therefore, a 
method that can monitor the pharmacokinetic parameters of 
cyclophosphamide is needed to determine the relationship between 
drug dosage and its efficacy. 
Quantitative analytical methods of cyclophosphamide and 4-OHCP 
have been described previously using High-Performance Liquid 
Chromatography (HPLC) [4] and Liquid Chromatography-Tandem 
Mass Spectrometry (LC-MS/MS) [5-7]. However, quantitative 
analytical methods of cyclophosphamide and 4-OHCP in DBS 
simultaneously using UPLC-MS/MS have never been done before. 
UPLC is a technical advancement of liquid chromatography where 
there are innovations in instrumentation and particle size to 
improve the resolution, speed, and sensitivity of the method [8]. 
4-OHCP metabolites are unstable in biological fluids such as in 
plasma, which has a half-life of 6 min [7]; this can be overcome by 
performing derivatization procedures prior to analysis [7, 9, 10]. In 
this study, an optimization and validation method for the analysis of 
cyclophosphamide and 4-OHCP in DBS was carried out using UPLC-
MS/MS. Validation parameters are tested according to the 
requirements of the Guidelines on Bioanalytical Method Validation 
by the European Medicines Agency in 2011. 
Cancer patients who receive cytostatic therapy are the priority of 
therapeutic drug monitoring to ensure that patients receive safe, 
effective and rational drugs, so it will minimize drug-related 
problems and optimize therapeutic effects [11]. After obtaining an 
optimal and valid method, the method was applied by analyzing 
dried blood spot samples of breast cancer patients in “Dharmais” 
Cancer Hospital as one of the effort for therapeutic drug monitoring. 
DBS samples were analyzed at Cmax 
MATERIALS AND METHODS 
and elimination phase. 
Equipment 
Ultra high-performance liquid chromatography (Waters Xevo TQD 
Triple Quadrupole) consisting of Quartenary Solvent Manager 
(Acquity UPLC H-Class), Sample Manager (Acquity UPLC), Nitrogen 
generator compressor (PEAK Scientific), UPLC Acquity column BEH 
C18 (100 mm x 2.1 mm) 1.7 μm, a triple quadrupole (Xevo TQD) 
mass analyzer with an ionization source (ZsprayTM) 
Materials 
Cyclophosphamide (Sigma Aldrich);4-OHCP-d4 Kit (Santa Cruz 
Biotechnology); HMP (Sigma Aldrich); semicarbazide hydrochloride 
(Sigma Aldrich); methanol, acetonitrile and formic acid, were 
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purchased from Merck Indonesia; aqua dest; and blood (Indonesian 
Red Cross). 
Method was applied on dried blood spot samples of 17 breast cancer 
patients who received cyclophosphamide. Patients received 700-
1114 mg/m2
The inclusion criteria of patients such as:  
 doses of cyclophosphamide. Blood samples were 
collected at 2 h and 4 h after administration. 
a. Patient of Dharmais Cancer Hospital. 
b. Receive cyclophosphamide as their chemotherapy regiment 
c. Patients age is 18-65 y old during the blood collection 
The exclusion criteria of patients such as:  
a. Patients is not willing to take part in the research and not signing 
the informed consent. 
Stock solution 
A 10 mg cyclophosphamide was dissolved in methanol until a 
concentration of 1 mg/ml cyclophosphamide was obtained. A 2.5 mg 
4-OHCP was dissolved with methanol until a concentration of 0.25 
mg/ml 4-OHCP was obtained. A 10 mg HMP as internal standard was 
dissolved with methanol until a concentration of 1 mg/ml HMP was 
obtained. 
Liquid chromatography-mass spectrometry instrument and 
condition 
The UPLC-MS/MS system consisted of a binary pump, autosampler, 
C18 Acquity BEH column (1.7 μm, 100 mm × 2.1 mm, Waters, 
Milford, MA, USA) using Van Guard TM BEH 1.7 μm precolumn, and 
mass spectrometry type quadrupole (Xevo TQD, Waters). The 
separation was performed using a mobile phase of 0.01% formic 
acid in water-methanol (50:50, v/v) with isocratic elution mode at 
0.3 ml/min for 4 min, column temperature of 30 °C, and an 
ionization method of ESI+. The quantitation was conducted using 
multiple reaction monitoring (MRM) and the quantitation traces 
were 260.968>139.976 for cyclophosphamide, 338.011>224.979 for 
4-OHCP-semicarbazide (4-OHCP-SCZ), and 180.17>92.08 for HMP. 
The injection volume was 10 μl. 
Derivatization solution 
Semicarbazide hydrochloride standard was dissolved with 10 ml of 
50 mmol potassium phosphate (pH 7.4) buffer until 2 M 
concentration was acquired. 
Optimization of derivatization procedure 
The derivatization procedure is done by applying 2 M semicarbazide 
hydrochloride on DBS paper, then dried for 2 h prior to blood 
spotting. Furthermore, the blood containing the analyte was applied 
on paper and sample preparation was carried out. The volume of 
derivative solution tested was 10 µl, 20 µl, 30 µl, 40 µl, and 50 µl.  
Optimization of sample preparation 
Optimization of sample preparation began with the selection of 
extraction methods between protein precipitation with methanol, 
liquid-liquid extraction with ethyl acetate-acetonitrile, and protein 
precipitation followed by liquid-liquid extraction. The next step is 
optimization of selected extraction methods. First, blood spotting 
volume was optimized for 10 µl; 20 µl; and 30 µl, then the DBS paper 
was left to dry at room temperature and was optimized for 1; 2; and 
3 h. Blood spots were cut and put into 1.5 ml microtube, then 20 µl 
HMP 1 µg/ml solution as the internal standard was added to the 
microtube and vortex mixed for 20 s. After that, the mixture was 
extracted with methanol and acetonitrile with the following 
combination: 1:0 v/v; 1:1 v/v; 1:2 v/v; 2:1 v/v; and 0:1 v/v and the 
volume was optimized for 200 µl; 500 µl; 800 µl; and 1000 µl. The 
mixture was vortex mixed, and was optimized for 4; 5; and 6 min, 
sonication was optimized for 5; 10; and 15 min, and centrifugation 
optimization was performed for 10 min at 5223.296 g; 8161.4 g; and 
11752.416 g. A total of 900 µl of supernatants were evaporated at 60 
°C for 20 min under N2
Method validation 
 gas flow. The residue was reconstituted with 
100 μl of mobile phase (0,01% formic acid in water-methanol = 
50:50 v/v), vortex mixed for 20 s, and centrifuged for 5 min at 
1147.068 g. Finally 10 μl of aliquot was injected into the 
chromatography system. 
The full validation of cyclophosphamide and 4-OHCP analysis 
method in DBS with parameters such as selectivity, carry over, 
LLOQ, linearity of calibration curve, accuracy and precision, 
recovery, dilution integrity, matrix effect, and stability [12]. 
This study was approved by the Ethics Committee of “Dharmais” 
Cancer Hospital (No.037/KEPK/III/2018). 
Application of the method-sampling procedure 
"Dharmais" Cancer Hospital patients was selected as the subject of 
the study according to the inclusion and exclusion criteria. Patients 
were given explanations related to the research and if the patients 
willing to be the subject, patients would sign an informed consent. 
Blood samples were taken by finger prick method at 2 and 4 h after 
cyclophosphamide regiment chemotherapy was given to the 
patients. 
RESULTS 
Optimization of derivatization procedure  
The optimum derivatization procedure was done by applying 20 µl 
of semicarbazide hydrochloride 2 M on DBS paper, then dried for 2 h 
prior to blood spotting. Furthermore, the blood containing the 
analyte was applied on paper and sample preparation was carried 
out.  
Optimization of sample preparation 
The optimum sample preparation was obtained by protein 
precipitation. Blood containing analytes was spotted 30 µl on DBS 
paper and left to dry at room temperature for 3 h. Blood spots were 
cut and put into 1.5 ml microtube, then 20 µl HMP 1 µg/ml solution 
as the internal standard was added to the microtube and vortex 
mixed for 20 s. After that, the mixture was extracted with 1000 µl 
methanol-acetonitrile = 2:1 v/v. The mixture was vortex mixed for 4 
min, sonication for 15 min, and centrifugation was performed for 10 
min at 11752.416 g. A total of 900 µl of supernatants were 
evaporated at 60 °C for 20 min under N2
Method validation 
 gas flow. The residue was 
reconstituted with 100 μl of the mobile phase, vortex mixed for 20 s, 
and centrifuged for 5 min at 1147.068g. Afterward, 10 μl of aliquot 
was injected into the chromatography system. 
a. LLOQ and calibration curve 
The LLOQ of cyclophosphamide was 50ng/ml with CV of 4.42% and 
%diff between 7.16% to 19.62% and 4-OHCP was 10ng/ml with CV 
of 6.43% and %diff between-18.27% to-6.76%. The calibration 
curve was linear in the concentration range of 50–30000ng/ml for 
cyclophosphamide with correlation coefficient (r)>0.9972 and 10–
1000ng/ml for 4-OHCP with correlation coefficient (r)>0.9983. 
Calibration curve was calculated with a weighted linear curve fit 
equation 1/x [13]. 
b. Selectivity 
The selectivity was performed on LLOQ concentrations and blanks 
using six different blood sources. The results show that the 
interference or impurity on the retention time of analytes and 
internal standard is still meet the criteria<20% of LLOQ 
concentration and<5% for the internal standard according to 
European Medicines Agency guideline of bioanalytical method 
validation. The chromatogram of the blank sample can be seen in fig. 
1. The chromatogram of cyclophosphamide, 4-OHCP-SCZ, and HMP 
with four-level concentrations which was LLOQ, Quality Control Low 
(QCL), Quality Control Medium (QCM), Quality Control High (QCH) 
can be seen in fig. 2. 
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Fig. 2: The chromatogram of LLOQ, QCL, QCM, QCH, and ULOQ concentration 
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Table 1: Data of carry over 
Blank sample Cyclophosphamide carry over (%) 4-OHCP carry over (%) Internal standard carry over (%) 
Blank 1 9.75 2.33 4.37 
Blank 2 8.11 1.22 3.31 
Blank 3 8.84 4.84 2.01 
Blank 4 7.16 4.61 3.19 
Blank 5 10.11 1.62 3.73 
Average 8.80 2.92 3.32 
 
c. Carry over 
The result shows no carry over in blank sample after injection of the 
highest concentration (ULOQ) sample. The carry over percentage 
still meets the requirements for analytes<20% and<5% for the 
internal standard. The result can be seen in table 1. 
d. Accuracy, precision, and recovery 
This research performs accuracy and precision in within-run and 
between-run. The test was performed using five replicates on 
each of four concentrations which contain both 
cyclophosphamide and 4-OHCP, such as LLOQ (50 and 10 
ng/ml); QCL (200 and 40 ng/ml), QCM (15000 and 500 ng/ml) 
and QCH (24000 and 800 ng/ml) for each time of analysis 
(within-run) and performed as many as three times the analysis 
of at least 2 different d (between-run). Accuracy is a parameter 
to see the proximity of the measured concentration results in the 
analysis with the actual concentration and represented by the 
%diff (bias) value, whereas the precision is performed to see the 
proximity between the repetitions of the measurement analytes 
represented by the CV value. The method was accurate and 
precise because all values met the requirements that bias (%diff) 
and CV for LLOQ<20% while for other concentration levels<15%. 
The result can be seen in table 2 and 3. 
 
Table 2: Data of within-run accuracy and precision 
Compounds Actual conc. (ng/ml) Meas conc (Average±SD; ng/ml) %CV %diff 
CP 50.00 47.45±5.25 11.07 -17.69 to 10.11 
200.00 197.01±19.31 9.80 -11.08 to 10.08 
15000.00 13130.11±183.47 1.40 -14.42 to-11.29 
24000.00 21056.89±582.25 2.77 -14.78 to-8.36 
4-OHCP 10.00 8.39±0.34 4.04 -19.92 to-11.02 
40.00 34.83±0.45 1.30 -13.82 to-11.40 
500.00 442.26±10.09 2.28 -14.12 to-8.57 
800.00 709.72±24.03 3.39 -13.54 to-6.21 
 
Table 3: Data of between-run accuracy and precision 
Compounds Actual conc. (ng/ml) Meas conc (Average±SD, ng/ml) %CV %diff 
CP 50.00 47.45±5.25 11.07 -17.69 to 19.05 
200.00 197.01±19.31 9.80 -11.08 to 14.30 
15000.00 13130.11±183.47 1.40 -14.72 to 10.84 
24000.00 21056.89±582.25 2.77 -14.78 to-0.48 
4-OHCP 10.00 8.39±0.34 4.04 -19.92 to 13.17 
40.00 34.83±0.45 1.30 -13.82 to-6.98 
500.00 442.26±10.09 2.28 -14.12 to 14.18 
800.00 709.72±24.03 3.39 -14.25 to-2.18 
 
Besides accuracy and precision, recovery was conducted to know 
the extraction efficiency. The recovery was calculated by comparing 
the area of analyte obtained after extraction with the area of 
standard analyteat the same concentration. Recovery of 
cyclophosphamide at three levels of concentration QCL, QCM, and 
QCL was 28.95–34.01% and 4-OHCP was 25.88–33.84%. 
e. Dilution integrity 
Dilution integrity was performed to determine whether dilutions 
carried out during the analysis affects accuracy and precision. The 
test was performed with a concentration above ULOQ or two times 
the QCH concentrations of both cyclophosphamide and 4-OHCP 
48000 ng/ml and 1600 ng/ml, diluted to half (24000and 800 ng/ml) 
and one quarter (12000and 400 ng/ml) using a whole blood. The 
analysis was conducted in five replicates on each dilution and 
observed the accuracy and precision parameters. The result showed 
that until one quarter dilution, the CV and %diff<15%. 
f. Matrix effect 
Matrix effect was conducted because the analysis of 
cyclophosphamide and 4-OHCP was using mass spectrometry. The 
matrix effect describes the presence of other compounds outside the 
analytes and internal standard in the ionization of the analytes and 
the internal standard in the ionization process. This effect was 
represented by the matrix factor by calculating the percentage 
between the area of analytes added after the blank extraction 
process with the standard solution area. The result can be seen in 
table 4. 
 
Table 4: Data of matrix effect of CP and 4-OHCP in DBS 
Compounds Actual Conc 
(ng/ml) 
Matrix factor Internal standard normalized matrix factor 
Matrix factor %CV Matrix factor %CV 
(Average±SD; %)  (Average±SD; %)  
CP 50.00 87.27±2.02 2.32 0.97±0.06 6.43 
24000.00 80.45±5.56 6.91 0.89±0.08 8.84 
4OHCP 10.00 77.74±5.70 7.33 0.86±0.09 10.10 
800.00 87.46±6.51 7.44 0.97±0.09 8.84 
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g. Stability 
The stability test was performed to ensure that the storage condition 
and sample preparation not affecting the concentration of the 
analytes. The stability test was performed using QCL and QCH 
samples of each of the three replicates. For short-term stability tests, 
samples were stored at room temperature for 24 h. The results 
showed that both cyclophosphamide and 4-OHCP was stable in DBS 
for at least 24 h at room temperature. The long-term stability tests 
also performed in a freezer temperature of-80 °C in the periods of 0, 
7, 14 d and post preparation stability (autosampler). The stability 
study results showed that cyclophosphamide was stable for at least 
14 d, 4-OHCP for at least 7 d in DBS at-80 °C and was stable for at 
least 24 h in the autosampler. The stock solution of 
cyclophosphamide, 4-OHCP, and HMO was stable for at least 14 d in 
the suitable storage condition. 
 
Table 5: Data of stability test result of CP and 4-OHCP in DBS 
Stability test Stable at least 
CP 4OHCP 
Short-term stability (24 h, 25 °C) 24 h 24 h 
Long-term stability (freezer-80 °C) 14 d 7 d 
Auto sampler (24 h) 24 h  24 h 
 
Application of the methods 
Cyclophosphamide and 4-OHCP were found in 17 of 17 samples of 
DBS. The average level of cyclophosphamide 2 h after administration 
was 18872.498 ng/ml with CV 42.91% and the average level of 
cyclophosphamide 4 h after administration was 14152.095 ng/ml 
with CV 44.37%. Whereas, the average level of 4-OHCP in 17 cancer 
patients 2 h after administration was 123.703 ng/ml with CV 
41.15% and an average level of 4-OHCP 4 h after administration was 
65.551 ng/ml with CV 46.15%. Data can be seen at table 6. 
 
Table 6: Data and result of analysis of cancer patients 




SN 01 39 FAC 761 2 h 11351.887 85.951 
4 h 16068.021 82.923 
SN 02 45 FAC 810 2 h 16428.075 75.961 
4 h 17268.697 78.280 
SN 03 51 FAC 732 2 h 13157.874 70.874 
4 h 15101.936 68.972 
SN 04 58 FAC 780 2 h 26150.655 246.362 
4 h 15993.924 151.130 
SN 05 41 FAC 920 2 h 16463.489 132.185 
4 h 12680.858 49.545 
SN 06 53 TC 960 2 h 21175.842 160.130 
4 h 14090.253 62.488 
SN 07 44 FAC 930 2 h 21446.954 159.699 
4 h 16175.628 51.391 
SN 08 38 FAC 750 2 h 14220.215 89.002 
4 h 7067.737 39.078 
SN 09 52 FAC 770 2 h 31091.169 90.261 
4 h 15460.019 47.877 
SN 10 52 FAC 710 2 h 19786.121 109.894 
4 h 18235.898 78.805 
SN 11 44 PTX-C 1114 2 h 37024.403 134.248 
4 h 28033.338 82.774 
SN 12 51 PTX-C 948 2 h 35869.579 207.871 
4 h 24545.752 101.210 
SN 13 43 FAC 900 2 h 11578.801 99.831 
4 h 8206.822 58.059 
SN 14 39 FAC 760 2 h 13206.363 138.825 
4 h 6045.980 35.962 
SN 15 35 FAC 720 2 h 13102.216 82.390 
  4 h 10591.826 33.155 
SN 16 47 FAC 800 2 h 12671.848 131.148 
4 h 7404.476 58.688 
SN 17 48 FAC 700 2 h 6106.981 88.315 
4 h 7614.457 34.022 
 
DISCUSSION 
Mass detection was carried out using a positive Electrospray 
Ionization (ESI). Positive ESI mode is used because analyte can be 
protonated. Cyclophosphamide produces a parent ion with m/z 
260.968, molecular formula C7H16Cl2N2O2P+and daughter ion with 
m/z 139.978, molecular formula C4H8Cl2N+. In addition, the 
semicarbazone 4-OHCP-d4 derivative produces a parent ion with 
m/z 338.011, molecular formula C8H14D4Cl2N5O3P+and daughter 
ion with m/z 224.979, molecular formula C4H6D4Cl2N2O2P+. HMP 
produced parent ion with m/z 180.17, molecular formula 
C6H19N3OP+and daughter ion with m/z 92.08, molecular formula 
C2H7NOP+. Acquity UPLC BEH C18 column and VanguardTM
 The BEH C18 column is nonpolar with the mobile phase of 0.01% 
formic acid-methanol (50:50) is polar, so this analysis used reverse-
phase chromatography system. 
 Acquity 
BEH precolom was used for analysis. The mobile phase used was 
0.01% formic acid-methanol (50:50) with isocratic elution for 4 min, 
a flow rate of 0.3 ml/min, and a column temperature of 30 °C [5]. 
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UPLC-MS/MS instrument and condition in this study was developed 
for the first time by Harahap, Samuel, Andalusia, and Syafhan by the 
year of 2016. In this study, the chromatographic condition was 
applied to develop a new bio sampling method, called DBS.4-OHCP 
as cyclophosphamide’s metabolite was very unstable against the 
presence of O2
DBS preparation was conducted using protein precipitation. This 
method was chosen because it cleans the analytes of many 
impurities in the sample and resulting the highest area of the 
analyte. The optimization was performed by methanol and 
acetonitrile as a combination of extracting solution because they are 
polar so the analytes will be extracted into the solvent. Besides, that 
solvent also have been used on the extraction of ifosfamid and 
cyclophosphamide in DBS [16]. The optimum sample preparation 
were obtained by protein precipitation using 1000 µl methanol-
acetonitrile = 2:1 v/v. The mixture was vortex mixed for 4 min, 
sonication for 15 min, and centrifugation was performed for 10 min 
at 11752.416g. The supernatants were evaporated and the residue 
was reconstituted with 100 μl of the mobile phase, vortex mixed for 
20 s, and centrifuged for 5 min at 1147.068g. Afterward, 10 μl of 
aliquot was injected into the chromatography system. The 
optimization results were selected based on the area of analytes and 
the internal standard also chromatogram form of each compound. 
 [14]. Therefore, the derivatization procedure is 
carried out prior to analysis. Derivatization in this study was carried 
out using semicarbazide hydrochloride to form semicarbazone 
derivatives [5, 14]. The procedure of derivatization was performed 
before the blood containing the analytes was applied on the DBS 
paper. The procedure of derivatization was developed first by Mess, 
Taillon, and Côté by the year of 2012 [15] to derivate racecadotril’s 
metabolite, thiorphan with 2-bromo-3’-metoxyacetophenon because 
it was unstable of oxidation in biology matrix. 
After acquiring the optimum condition, the analysis method 
validation was conducted. Based on all value results of validation 
that met the requirements of Guideline on Bioanalytical Method 
Validation [12], it can be concluded that the developed method was 
valid. This research showed LLOQ was 50 ng/ml for 
cyclophosphamide and 10 ng/ml for 4-OHCP. This value fulfilled the 
European Medicines Agency requirement that was 5% of Cmax
The average levels of cyclophosphamide and 4-OHCP at the 2
. 
Therefore this new method of bio samping using DBS can be applied 
in pharmacokinetic studies or bioequivalence studies. 
ndh was 
higher than the 4th h. This is in accordance with previous research that 
at the 2 h after administration is Cmax
From the results,method that had been developed before could be 
applied on the analysis of cyclophosphamide and 4-OHCPfor the 
therapeutic drug monitoring. Cyclophosphamide metabolite, 4-
OHCP, will be converted to phosphoramide mustard which can 
alkylate DNA so it can provide a cytotoxic effect on cancer cells. 
 time and 4 h after administration 
is an elimination time of both compounds [16, 17]. Drug and their 
metabolites level in each patient can be different. This can be due to 
the expression level of the CYP enzyme, especially CYB2B6 in the liver, 
and also the individual capacity to the enzyme. In addition, the level of 
expression and activity of ALDH isoenzymes can also vary between 
individuals. Beside polymorphism factors, other factors such as 
disease status, weight, age, food, dose, stress, dysfunction of other 
organs such as the liver and kidneys, etc can also affect both compouds 
level. Graphic of both compounds level can be seen at fig. 3. 
In this research there were 17 subjects from Dharmais Cancer 
Hospital to verify the applicability of this method. In order to 
establish a reliable pharmacokinetics data, more samples are needed 
to be taken from a bigger pool of subject. 
 
 
Fig. 3: Bar chart of cyclophosphamide and 4-OHC plevel 
 
CONCLUSION 
In conclusion, this method for quantifying cyclophosphamide and 4-
OHCP in DBS was successfully developed, validated, and can be 
applied on breast cancer patients for therapeutic drug monitoring. 
The LLOQ obtained in this study was 50 ng/ml for 
cyclophosphamide and 10 ng/ml for 4-OHCP. This method is 




All authors have contributed equally. 
CONFLICT OF INTERESTS 
Declared none 
REFERENCES 
1. LaPlant K, Louzon P. Anticancer drug. In: K Whalen, R Finkel, T 
Panavelil. editors. Lippincott Ilustrated Reviews: 
Pharmacology. 6th ed. China: Wolters Kluwer; 2015. p. 587-
617. 
2. Chabner BA. Cytotoxic agent. In: L Brunton, B Knollmann, B 
Chabner. editors. Goodman and gilman's the pharmacological 
basis of therapeutics. 12th ed. New York: McGraw Hill; 2011. p. 
1677-730.  
3. Veal GJ, Cole M, Chinnaswamy G, Sludden J, Jamieson D, 
Errington J, et al. Cyclophosphamide pharmacokinetics and 
pharmacogenetics in children with B-cell non-hodgkin’s 
lymphoma. Eur J Cancer 2016;55:56-64. 
4. Kalhorn TF, Howald WN, Cole S, Phillips B, Wang J, Slattery JT, 
et al. Rapid quantitation of cyclophosphamide metabolites in 
plasma by liquid chromatography–mass spectrometry. J 
Chromatogr B 2006;835:105-13. 
Harahap et al. 
Int J App Pharm, Vol 12, Issue 4, 2020, 119-125 
125 
5. Harahap Y, Samuel C, Andalusia R, Syafhan NF. Analysis of 4-
hydroxycyclophosphamide in cancer patients plasma 
fortherapeutic drug monitoring of cyclophosphamide. Int J 
Pharm Pharm Sci 2016;8:194-200.  
6. Ekhart C, Gebretensae A, Rosing H, Rodenhuis S, Beijnen JH, 
Huitema ADR. Simultaneous quantification of 
cyclophosphamide and its active metabolite 4-
hydroxycyclophosphamide in human plasma by high-
performance liquid chromatography coupled with electrospray 
ionization tandem mass spectrometry (LC–SM/SM). J 
Chromatogr B 2007;854:345-9. 
7. Sadagopan N, Cohen L, Roberts B, Collard W, Omer C. Liquid 
chromatography–tandem mass spectrometric quantitation of 
cyclophosphamide and its hydroxy metabolite in plasma and 
tissue for determination of tissue distribution. J Chromatogr B 
2001;759:277-84. 
8. Hussain S, Shaikh T. Ultra high performance liquid 
chromatography (UPLC): a new trend in analysis. World J 
Pharm Res 2016;5:387–94. 
9. Bai F, Fraga CH, Tagen M, Schaiquevich P, Hagedorn N, Stewart 
CF. Simulaneous Determination of cyclophosphamide and 
carboxyethylphosphoramide mustard in human plasma using 
online extraction and electrospray tandem mass spectrometry 
(HTLC-ESI-MS/MS). J Chromatogr B 2009;877:1709-15. 
10. Baumann F, Lorenz C, Jaehde U, Preiss R. Determination of 
cyclophosphamide and its metabolites in human plasma by 
high-performance liquid chromatography–mass 
spectrometry. J Chromatogr B 1999;729:297-305.  
11. Ministry of Health Indonesia. Infodatin: Pusat Data 
danInformasi Kementerian Kesehatan Republik Indonesia. 
Jakarta; 2015. p. 3. 
12. European Medicines Agency. Guideline on Bioanalytical Method 
Validation, Sciences Medicines Health. London: European 
Medicines Agency; 2011. 
13. Almeida AM, Castel Branco M, Falcao A. Linear regression for 
calibration lines revisited: weighting schemes for bioanalytical 
methods. J Chromatogr B 2002;774:215-22. 
14. Moldoveanu S, David V. The role of derivatization in 
chromatography. Modern Sample Preparation for 
Chromatography; 2015. p. 307–31. 
15. Mess J, Taillon M, Cote C. Dried blood spot on-card 
derivatization : an alternative form of sample handling to 
overcome the instability of thiorphan in biological matrix. 
Biomed Chromatogr 2012;26:1617-24. 
16. Torres LM, Espinova LR, Pacheco JLC, Navas CF, Demetrio JA, 
Medina RA, et al. A new method to quantify ifosfamide blood 
levels using dried blood spots and UPLC-MS/MS in paediatric 
patients with embryonic solid tumours. Plos One 2015;10:1-13.  
17. Joy MS, La M, Wang J, Bridges AS, Hu Y, Hogan SL, et al. 
Cyclophosphamide and 4-hydroxycyclophosphamide 
pharmacokinetics in patients with glomerulonephritis 
secondary to lupus and small vessel vasculitis. Br J Clin 
Pharmacol 2012;74:445–55. 
18. Anderson L, Ludeman S, Colvin O, Grochow L, Strong J. 
Quantitation of 4-hydroxycyclophosphamide/aldophosphamide 
in whole blood. J Chromatogr B 1995;667:247-57.  
 
